Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Deborah L, Wolbrette"'
Autor:
John van Harskamp, Gregory M. Caputo, Gerald V. Naccarelli, Barbara Bentz, Frendy D Glasser, Mohammed Ruzieh, Douglas L. Leslie, Deborah L. Wolbrette, Thomas W. Abendroth, Jovan Plamenac, Stephen Wasemiller, Kevin Mills, Nathan McConkey, Mauricio Sendra-Ferrer
Publikováno v:
The American Journal of Medicine. 134:e366-e373
BACKGROUND Multiple registries have reported that >40% of high-risk atrial fibrillation patients are not taking oral anticoagulants. The purpose of our study was to determine the presence or absence of active atrial fibrillation and CHA2DS2-VASc (Con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::072169dca94bd6a7261174329de9cb27
https://doi.org/10.1016/j.amjmed.2020.11.024
https://doi.org/10.1016/j.amjmed.2020.11.024
Autor:
Gerald V. Naccarelli, Deborah L. Wolbrette, Vadim Levin, Soraya Samii, Javier E. Banchs, Erica Penny-Peterson, Mario D. Gonzalez
Publikováno v:
Clinical Medicine Insights: Cardiology, Vol 2011, Iss 5, Pp 103-119 (2011)
Externí odkaz:
https://doaj.org/article/b256e4f8e4124679b961524d2a719617
Autor:
John van Harskamp, Kevin Mills, Gregory M. Caputo, Douglas L. Leslie, Mauricio Sendra-Ferrer, Jovan Plamenac, Frendy D Glasser, Stephen Wasemiller, Deborah L. Wolbrette, Nathaniel McConkey, Mohammed Ruzieh, Thomas W. Abendroth, Gerald V. Naccarelli, Barbara Bentz
Publikováno v:
Circulation. 142
Introduction: Guidelines recommend oral anticoagulants (OAC) in high risk atrial fibrillation (HRAF) patients. It has been reported that >40% of such patients are not taking an OAC. We observed that active AF often was not present in patients labeled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::614f86d271353a03de0eeed7c9057dd9
https://doi.org/10.1161/circ.142.suppl_3.12678
https://doi.org/10.1161/circ.142.suppl_3.12678
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 24:3-10
Dofetilide is a class III antiarrhythmic agent approved by the Food and Drug Administration for the conversion of atrial fibrillation and atrial flutter and maintenance of sinus rhythm in symptomatic patients with persistent arrhythmia. Drug trials s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a50ef1673ffb9c3fa14901a922ff8d28
https://doi.org/10.1177/1074248418784288
https://doi.org/10.1177/1074248418784288
Publikováno v:
Heart Rhythm. 18:S431
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7700ceb26c7843dd2dfe199edfe626f
https://doi.org/10.1016/j.hrthm.2021.06.1065
https://doi.org/10.1016/j.hrthm.2021.06.1065
Autor:
Samuel Faber, Gregory M. Caputo, Thomas W. Abendroth, Mario D. Gonzalez, Deborah L. Wolbrette, Soraya Samii, Mauricio Sendra-Ferrer, Gerald V. Naccarelli, Sarah K. Hussain
Publikováno v:
Cardiovascular Innovations and Applications, Vol 1, Iss 2, Pp 157-164 (2016)
Stroke is the most common complication of atrial fibrillation (AF). Guidelines recommend anticoagulant treatment in patients with CHA2DS2VASc scores of >2. Registry data suggests that almost half of patients who should be on therapeutic anticoagulati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6382dc3cd6f74b66d23d63f445b26f02
http://www.ingentaconnect.com/content/cscript/cvia/2016/00000001/00000002/art00004
http://www.ingentaconnect.com/content/cscript/cvia/2016/00000001/00000002/art00004
Publikováno v:
Journal of the American College of Cardiology. 72(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39ec70e58348b0d1adc8308a346c28b8
https://pubmed.ncbi.nlm.nih.gov/30049309
https://pubmed.ncbi.nlm.nih.gov/30049309
Autor:
Erica Penny-Peterson, Javier E. Banchs, Gerald V. Naccarelli, William R. Davidson, Mario D. Gonzalez, Deborah L. Wolbrette, Michelle J. Nickolaus, John Kelleman, Soraya Samii, Sallie K. Young, Jennifer Grando-Ting, Giselle A. Baquero
Publikováno v:
Congenital Heart Disease. 9:221-227
Background Atrial tachyarrhythmias (AT) including atrial fibrillation (AF), atrial flutter (AFL), and atrial tachycardia represent a clinical challenge in the adult with congenital heart disease (CHD). Dofetilide (D) is a rapidly activating delayed r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60330b37d7b11cd84e49e7c0ae6ba025
https://doi.org/10.1111/chd.12129
https://doi.org/10.1111/chd.12129
Autor:
Soraya Samii, Paras Karmacharya, Sarah K. Hussain, Gerald V. Naccarrelli, Anene Ukaigwe, Pragya Shrestha, Deborah L. Wolbrette, Mario D. Gonzalez
Publikováno v:
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing. 48(2)
Apixaban is a Factor Xa inhibitor increasingly being used for stroke prevention in atrial fibrillation (AF). Although several studies have been done, the efficacy and safety of apixaban during the peri-procedural period of AF ablation remains unclear
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6358ffc939848e88171c0ab56503f3ab
https://pubmed.ncbi.nlm.nih.gov/27771820
https://pubmed.ncbi.nlm.nih.gov/27771820
Autor:
Joshua B. Skibba, Bharathi Upadhya, Erica Penny-Peterson, Mario D. Gonzalez, Javier E. Banchs, Soraya Samii, Gerald V. Naccarelli, Gurpal Singh, Deborah L. Wolbrette
Publikováno v:
Revista Iberoamericana de Arritmología. 3:6-14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a85e7158de946e3bf69c04f53594531
https://doi.org/10.5031/v3i1.ria10193
https://doi.org/10.5031/v3i1.ria10193